Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Gastroenterology

• Publication date

  2012-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1053/j.gastro.2012.06.009PMID 22710188
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2014cited by this paper
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cited by this paper
• Licensing Virus-Specific T Cells to Secrete the Neutrophil Attracting Chemokine CXCL-8 during Hepatitis B Virus Infection

  2011cited by this paper
• T cell exhaustion

  2011cited by this paper
• Reasons to consider earlier treatment of chronic HBV infections

  2011cited by this paper
• IL-21 is pivotal in determining age-dependent effectiveness of immune responses in a mouse model of human hepatitis B.

  2011cited by this paper
• Antiviral intrahepatic T-cell responses can be restored by blocking programmed death-1 pathway in chronic hepatitis B.

  2010cited by this paper
• PD‐1/PD‐L1 pathway and T‐cell exhaustion in chronic hepatitis virus infection

  2010cited by this paper
• The Role of Chemokines in the Recruitment of Lymphocytes to the Liver

  2010cited by this paper
• Bioluminescence imaging allows measuring CD8 T cell function in the liver

  2010cited by this paper
• The molecular basis of the failed immune response in chronic HBV: therapeutic implications.

  2010cited by this paper
• Immune and Viral Profile from Tolerance to Hepatitis B Surface Antigen Clearance: a Longitudinal Study of Vertically Hepatitis B Virus-Infected Children on Combined Therapy

  2010cited by this paper
• High antigen levels are the cause of T cell exhaustion during chronic viral infection

  2009cited by this paper
• Hepatitis B virus infection.

  2009cited by this paper
• Host Ethnicity and Virus Genotype Shape the Hepatitis B Virus-Specific T-Cell Repertoire

  2008cited by this paper
• Combined lamivudine/interferon-alpha treatment in "immunotolerant" children perinatally infected with hepatitis B: a pilot study.

  2006cited by this paper
• Collagens are functional, high affinity ligands for the inhibitory immune receptor LAIR-1

  2006cited by this paper
• Cellular and molecular mechanisms of liver tolerance

  2006cited by this paper
• Longitudinal Analysis of CD8+ T Cells Specific for Structural and Nonstructural Hepatitis B Virus Proteins in Patients with Chronic Hepatitis B: Implications for Immunotherapy

  2004cited by this paper
• Hepatitis B virus infection--natural history and clinical consequences.

  2004cited by this paper
• LAG-3: a regulator of T-cell and DC responses and its use in therapeutic vaccination.

  2003cited by this paper
• Chronic hepatitis B.

  2001cited by this paper
• Chronic hepatitis B

  2001cited by this paper
• Antigen-Specific Primary Activation of CD8+ T Cells Within the Liver1

  2001cited by this paper
• The role of virus-specific CD8(+) cells in liver damage and viral control during persistent hepatitis B virus infection.

  2000cited by this paper
• A chemokine-to-cytokine-to-chemokine cascade critical in antiviral defense.

  2000cited by this paper
• The Role of Virus-Specific Cd8+ Cells in Liver Damage and Viral Control during Persistent Hepatitis B Virus Infection

  2000cited by this paper
• Direct ex vivo analysis of hepatitis B virus-specific CD8(+) T cells associated with the control of infection.

  1999cited by this paper
• Requirement of MIP-1 alpha for an inflammatory response to viral infection.

  1995cited by this paper
• Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1 alpha and MIP-1 beta

  1993cited by this paper

• High rate of functional cure in infants with chronic hepatitis B following a definite duration of antiviral treatment.

  2026cites this paper
• Hepatitis B virus RNA and hepatitis B surface antigen kinetics predict treatment outcomes in children with chronic hepatitis B.

  2026cites this paper
• EASL Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2025cites this paper
• Immune Checkpoints Determine the NK/NKT and T Cell Immunity in Chronic Hepatitis B

  2025cites this paper
• Management of Immune Tolerant Chronic Hepatitis B.

  2025cites this paper
• The Role of LAIR1 as a Regulatory Receptor of Antitumor Immune Cell Responses and Tumor Cell Growth and Expansion

  2025cites this paper
• Rapid whole-blood immune profiling reveals heterogeneous HBV-specific T cell response patterns independent of clinical disease phases.

  2025cites this paper
• Younger age predicts increased HBsAg loss in children with chronic hepatitis B on antiviral therapy: A systematic review and meta-analysis

  2025cites this paper
• Incidence and predictors of HBsAg loss in treatment-naïve children with immune-tolerant chronic hepatitis B after antiviral therapy.

  2025cites this paper
• Chronic Hepatitis B Infection: Patient Guidance

  2025cites this paper
• Activation of the Jak2/Stat3 pathway by ROS-dependent signaling cascades initiates hepatitis B virus-induced hepatic inflammatory responses

  2025cites this paper
• Predictive value of HBeAg titer dynamics for HBsAg clearance in pediatric chronic hepatitis B

  2025cites this paper
• Indian National Association for the Study of the Liver Position Statements on Prevention, Diagnosis, and Management of Hepatitis B Virus Infection in India.

  2025cites this paper
• The role of immune regulation in HBV infection and hepatocellular carcinogenesis

  2025cites this paper
• Immunotherapy Using HBV Vaccine Pulsed DCs and Induced T‐Cells Combined Antiviral Drugs in Treatment Naive CHB Patients‐A Multi‐Centre Phase II Study

  2025cites this paper
• Scientific and medical evidence informing expansion of hepatitis B treatment guidelines.

  2025cites this paper
• Virological Insights from ARC-520 siRNA and Entecavir Treated Chronically HBV-Infected Patients and Chimpanzees

  2025cites this paper
• Decoding HBV-specific adaptive immunity: from natural clearance to cure

  2025cites this paper
• Toward a better understanding of chronic hepatitis B virus infection

  2024cites this paper
• Addition of PEG‐interferon to long‐term nucleos(t)ide analogue therapy enhances HBsAg decline and clearance in HBeAg‐negative chronic hepatitis B

  2024cites this paper
• Determining optimal ALT cut‐off values for predicting significant hepatic histological changes in patients with normal ALT in the grey zone of chronic hepatitis B virus infection

  2024cites this paper
• Priming and Maintenance of Adaptive Immunity in the Liver.

  2024cites this paper
• Ex-vivo evaluation of Plasmodium falciparum-induced cytokine expression in chronic hepatitis B virus-infected and uninfected individuals

  2024cites this paper
• Stat3 activation-triggered transcriptional networks govern the early stage of HBV-induced hepatic inflammation

  2024cites this paper
• Significant liver histological change is common in HBeAg-positive chronic hepatitis B with normal ALT

  2024cites this paper
• Epidemiology and assessment of Hepatitis B positive children in Western Australia

  2024cites this paper
• Soluble Programmed Cell Death 1 Protein Is a Promising Biomarker to Predict Severe Liver Inflammation in Chronic Hepatitis B Patients

  2024cites this paper
• “Treat-all” Strategy for Patients with Chronic Hepatitis B Virus Infection in China: Are We There Yet?

  2024cites this paper
• Lassa virus persistence with high viral titers following experimental infection in its natural reservoir host, Mastomys natalensis

  2024cites this paper
• The immune response in chronic HBV infection

  2024cites this paper
• Therapeutic potential of co-signaling receptor modulation in hepatitis B

  2024cites this paper
• Long-term hepatitis B surface antigen response after finite treatment of ARC-520 or JNJ-3989

  2024cites this paper
• A Systematic Review of the Advances in the Study of T Lymphocyte Suppressor Receptors in HBV Infection: Potential Therapeutic Targets

  2024cites this paper
• Persistently high HBsAg levels during HBeAg‐seropositive stage predict lower risk of hepatocellular carcinoma in chronic hepatitis B patients

  2024cites this paper
• Expression patterns of immune checkpoint proteins and Plasmodium falciparum‐induced cytokines in chronic hepatitis B virus‐infected and uninfected individuals: A cross‐sectional study

  2024cites this paper
• Insights into Immune Exhaustion in Chronic Hepatitis B: A Review of Checkpoint Receptor Expression

  2024influential citation
• Estimating the key outcomes and hepatocellular carcinoma risk in patients in immune‐tolerant phase of chronic hepatitis B virus infection: A systematic review and meta‐analysis

  2024cites this paper
• Characterization of Hepatitis B Virus Transcripts in Chronically HBV-Infected Chimpanzees and Patients Treated with ARC-520 siRNA Demonstrates Transcriptional Silencing of cccDNA

  2024cites this paper
• Predictive role of early treatment dynamics of HBV RNA and HBcrAg for HBeAg seroconversion in children with chronic hepatitis B

  2024cites this paper
• Should Indications for Antiviral Therapy for Hepatitis B Be Broadened to Include Immune-Tolerant Patients, Inactive Carriers, or Patients in the “Gray Zone”?

  2024cites this paper
• The truth of the matter: will immune-tolerant chronic hepatitis B patients benefit from antiviral treatment?

  2023cites this paper
• The scientific basis of combination therapy for chronic hepatitis B functional cure

  2023cites this paper
• Quest for immunological biomarkers in the management of CHB patients

  2023cites this paper
• Why is the functional cure rate of young children with chronic hepatitis B receiving antiviral therapy considerably high?

  2023cites this paper
• Chronic Hepatitis B: Treat all Who Are Viremic?

  2023cites this paper
• Hepatocellular Carcinoma and Hepatitis: Advanced Diagnosis and Management with a Focus on the Prevention of Hepatitis B-Related Hepatocellular Carcinoma

  2023cites this paper
• The CD8+ T cell exhaustion mechanisms in chronic hepatitis B infection and immunotherapeutic strategies: a systematic review

  2023cites this paper
• eALT-F: A New Non-Invasive Staging Method to Identify Medium to High-Risk Patients with HCC from Ultra-High HBV Viral Load Population — China, 2010–2023

  2023cites this paper
• Therapeutic vaccination with lentiviral vector in HBV-persistent mice and two inactive HBsAg carriers.

  2023cites this paper
• Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B

  2023cites this paper
• Efficacy and Safety of Antiviral Therapy for Immune-tolerant Hepatitis B Viral Infection in Children: A Systematic Review and Meta-analysis

  2023cites this paper
• Research Progress on the Need for Antiviral Therapy in Chronic HBV Infected Patients with Normal ALT

  2023cites this paper
• What Is the Current Status of Hepatitis B Virus Viro-Immunology?

  2023cites this paper
• Management of Immune-Tolerant Patients with Chronic HBV Infection

  2023cites this paper
• EASL International Recognition Award Recipient 2023: Prof. Antonio Bertoletti.

  2023cites this paper
• New Approaches to Chronic Hepatitis B.

  2023cites this paper
• PreS1- targeting chimeric antigen receptor T cells diminish HBV infection in liver humanized FRG mice.

  2023cites this paper
• Antiviral therapy in hepatitis B virus-infected with immune-tolerant: A meta-analysis

  2023cites this paper
• Pathway to global elimination of hepatitis B: HBV cure is just the first step

  2023cites this paper
• Functional Cure of Chronic Hepatitis B with Antiviral Treatment in Children having High-level Viremia and Normal or Mildly Elevated Serum Aminotransferase

  2023cites this paper
• Hepatitis B virus serum RNA transcript isoform composition and proportion in chronic hepatitis B patients by nanopore long-read sequencing

  2023cites this paper
• PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B.

  2023cites this paper
• Inhibition of HBV replication by EVA1A via enhancing cellular degradation of HBV components and its potential therapeutic application.

  2023cites this paper
• Factors affecting HBV DNA suppression in chronic hepatitis B patients treated with tenofovir disoproxil fumarate

  2022cites this paper
• Viral Diagnosis of Hepatitis B and Delta: What We Know and What Is Still Required? Specific Focus on Low- and Middle-Income Countries

  2022cites this paper
• HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History

  2022cites this paper
• Perspectives on current controversial issues in the management of chronic HBV infection

  2022cites this paper
• Vitamin D role in hepatitis B: focus on immune system and genetics mechanism

  2022cites this paper
• The study of immune checkpoint inhibitors in chronic hepatitis B virus infection.

  2022cites this paper
• Toll-Like Receptor 7 Agonist RG7854 Mediates Therapeutic Efficacy and Seroconversion in Woodchucks With Chronic Hepatitis B

  2022cites this paper
• The efficacy of pegylated interferon alpha-2a and entecavir in HBeAg-positive children and adolescents with chronic hepatitis B

  2022cites this paper
• Proteomic characterization of the natural history of chronic HBV infection revealed by tandem mass tag-based quantitative proteomics approach

  2022cites this paper
• 만성 B형간염 면역관용기의 정의 및 치료

  2022cites this paper
• Early Treatment Consideration in Patients with Hepatitis B ‘e’ Antigen-Positive Chronic Infection: Is It Time for a Paradigm Shift?

  2022cites this paper
• TIGIT marks exhausted T cells and serves as a target for immune restoration in patients with chronic HBV infection.

  2022cites this paper
• Developing a cure for chronic hepatitis B requires a fresh approach

  2022cites this paper
• Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBeAg-positive chronic hepatitis B

  2022cites this paper
• Making child’s play of tolerance: Defining the immune‐viral interplay during combination entecavir and pegylated interferon therapy for immune‐tolerant hepatitis B infection

  2022cites this paper
• Diverse facets of MDSC in different phases of chronic HBV infection: Impact on HBV‐specific T‐cell response and homing

  2022cites this paper
• A novel model based on qAnti-HBc and conventional biomarkers for identifying significant liver injury among CHB patients with ALT ≤ ULN.

  2022cites this paper
• Changes in serum hepatitis B surface and e antigen, interferon‐inducible protein 10, and aminotransferase levels during combination therapy of immune‐tolerant chronic hepatitis B

  2022cites this paper
• Frequent alanine aminotransferase flares and promising antiviral therapy efficacy during the preschool age: An opportunity to achieve HBsAg loss in children with mother‐to‐child transmitted hepatitis B

  2022cites this paper
• Unmet Needs in Clinical Research Hepatitis B

  2021cites this paper
• Treatment for Viral Hepatitis as Secondary Prevention for Hepatocellular Carcinoma

  2021cites this paper
• On-treatment HBV RNA Dynamic Predicts Entecavir-induced HBeAg Seroconversion in Children with Chronic Hepatitis B: HBV RNA predicts HBeAg seroconversion.

  2021cites this paper
• Antiviral Therapy for Chronic HBV Infection With Persistently Normal Alanine Aminotransferase: Controversy and Consensus

  2021cites this paper
• Effects of intrauterine exposure to hepatitis B virus in foetuses.

  2021cites this paper
• Role of Immune Cells in Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma

  2021cites this paper
• Nucleos(t)ide Therapy and Long-Term Outcomes

  2021cites this paper
• Immunobiology and pathogenesis of hepatitis B virus infection

  2021cites this paper
• Optimize nucleot(s)ide analogues’ to prevent hepatocellular carcinoma in patients with chronic hepatitis B: a lesson from real-world evidence

  2021cites this paper
• Innate immunity in hepatitis B and D virus infection: consequences for viral persistence, inflammation, and T cell recognition

  2021cites this paper
• A Non-invasive Model for Predicting Liver Inflammation in Chronic Hepatitis B Patients With Normal Serum Alanine Aminotransferase Levels

  2021cites this paper
• Increased hepatitis B virus quasispecies diversity is correlated with liver fibrosis progression.

  2021cites this paper
• RNA Interference Therapy for Chronic Hepatitis B Predicts the Importance of Addressing Viral Integration When Developing Novel Cure Strategies

  2021cites this paper
• Viral quasispecies quantitative analysis: a novel approach for appraising the immune tolerant phase of chronic hepatitis B virus infection

  2021cites this paper
• HBV-Integration Studies in the Clinic: Role in the Natural History of Infection

  2021cites this paper
• Chronic hepatitis B: the demise of the ‘inactive carrier’ phase

  2021cites this paper
• Hepatitis B in Children - The Pursuit of a Hepatitis Free Future Generation.

  2021cites this paper
• Secondary prevention of hepatitis B virus‐related hepatocellular carcinoma with current antiviral therapies

  2021cites this paper